Hutchmed (HCM) said late Tuesday a phase III registration part of a clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia in China met its primary endpoint.

The study showed a durable hemoglobin response rate within weeks five to 24 of treatment, the company said.

Autoimmune hemolytic anemia is an autoimmune disorder characterized by the destruction of red blood cells.